3/20/2007

Analysts say the Australian biotech is a good bet to get U.S. FDA approval for its HIV drug apricitabine, which could place the firm in the sights of major drug companies. One analyst says the company could be a target for acquisition by GlaxoSmithKline or Gilead Sciences, which hold a large share of the HIV treatment market.

Related Summaries